CA2251724A1 - Compositions containing bacteriophages and methods of using bacteriophages to treat infections - Google Patents

Compositions containing bacteriophages and methods of using bacteriophages to treat infections Download PDF

Info

Publication number
CA2251724A1
CA2251724A1 CA002251724A CA2251724A CA2251724A1 CA 2251724 A1 CA2251724 A1 CA 2251724A1 CA 002251724 A CA002251724 A CA 002251724A CA 2251724 A CA2251724 A CA 2251724A CA 2251724 A1 CA2251724 A1 CA 2251724A1
Authority
CA
Canada
Prior art keywords
bacteriophage
bacterial
preparation
host
bacterial organism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251724A
Other languages
English (en)
French (fr)
Inventor
Paul Averback
Hossein A. Ghanbari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nymox Pharmaceutical Corp Canada
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251724A1 publication Critical patent/CA2251724A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002251724A 1996-04-15 1997-04-15 Compositions containing bacteriophages and methods of using bacteriophages to treat infections Abandoned CA2251724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1566396P 1996-04-15 1996-04-15
US60/015,663 1996-04-15

Publications (1)

Publication Number Publication Date
CA2251724A1 true CA2251724A1 (en) 1997-10-23

Family

ID=21772776

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251724A Abandoned CA2251724A1 (en) 1996-04-15 1997-04-15 Compositions containing bacteriophages and methods of using bacteriophages to treat infections

Country Status (6)

Country Link
US (3) US6121036A (enExample)
EP (1) EP0895534A1 (enExample)
JP (1) JP2000508322A (enExample)
AU (1) AU734420B2 (enExample)
CA (1) CA2251724A1 (enExample)
WO (1) WO1997039111A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
GB9809414D0 (en) * 1998-05-02 1998-07-01 Scottish Crop Research Inst Method
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US6440405B1 (en) * 1999-06-07 2002-08-27 University Of Delaware Quaternary ammonium functionalized dendrimers and methods of use therefor
WO2001050872A2 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages
US20040191224A1 (en) * 2000-01-11 2004-09-30 Intralytix, Inc. Method and device for sanitation using bacteriophages
US6485902B2 (en) 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
DE10042853A1 (de) * 2000-08-30 2002-04-25 Florian Lang Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen
AU2002221713A1 (en) * 2000-10-25 2002-05-06 Intercell Biomedizinische Forschulungs- Und Entwicklungs Ag Modified phage, comprising a non-lytic modification and expressing a kil-gene
MXPA03004182A (es) * 2000-11-13 2004-03-26 Univ Iowa State Res Found Inc Composiciones y metodos para reducir la cantidad de salmonella en el ganado.
US6461608B1 (en) * 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination
DE10115310A1 (de) * 2001-03-28 2002-10-10 Nodar A Daniela Bakteriophagen-Präparation
AU2002308467A1 (en) * 2001-04-19 2002-11-05 Biophage, Inc. Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
ES2283581T3 (es) * 2001-07-18 2007-11-01 Instytut Immunologii I Terapii Doswiadczalnej-Pan Procedimientos de preparacion de bacteriofagos polivalentes para el tratamiento de infeccines bascterianas.
PL354822A1 (en) * 2002-06-30 2004-01-12 Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu Method of receiving purified bacteriophage preparations and new applications of polysaccharide or its esterificated derivative
PT1458856E (pt) * 2001-12-13 2012-07-06 Nestle Sa Fagos isolados e sua utilização em produtos alimentares ou produtos alimentares para animais de estimação
US6759229B2 (en) * 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
ATE352564T1 (de) * 2002-03-04 2007-02-15 Nymox Corp Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle
GB0207021D0 (en) * 2002-03-25 2002-05-08 Univ Warwick Anti-bacterial agents
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
WO2003103578A2 (en) * 2002-06-05 2003-12-18 Iowa State University Research Foundation, Inc. Bacteriophage and enzymes lytic to salmonellae
RU2232808C1 (ru) * 2002-10-11 2004-07-20 Закрытое акционерное общество "ПИ - ПРО - ЛАЙФ" Биопрепарат на основе бактериофагов для профилактики и лечения сальмонеллеза животных
RU2244747C2 (ru) * 2002-11-01 2005-01-20 Закрытое акционерное общество "ПИ-ПРО-ЛАЙФ" Биопрепарат на основе бактериофагов для профилактики и лечения колибактериоза (эшерихиоза) животных
EP1560491A4 (en) * 2002-11-14 2008-04-30 Gangagen Inc BACTERIOPHAGE WITH MODIFIED HOLIN AND ITS USE
GB0300597D0 (en) * 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
EP2570130B1 (en) 2003-07-23 2014-11-26 Biocontrol Limited Therapeutic agents containing bacteriophages against P. aeruginosa
EP1677834B1 (en) * 2003-10-06 2014-01-08 Gangagen, Inc. Defined dose therapeutic phage
US20060153811A1 (en) * 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
AU2006268420B2 (en) * 2005-07-12 2012-06-28 Micreos B.V. Bacteriophage and their uses
JP2007084492A (ja) * 2005-09-22 2007-04-05 Hiroshima Univ バクテリオファージを含む、細菌性感染症治療用の薬剤
US20090053179A1 (en) * 2005-10-05 2009-02-26 Internalle, Inc. Method for using liberated dormant bacteriophage and environmental stress to reduce infectious bacteria
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US8178087B2 (en) * 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
US20070292397A1 (en) * 2006-06-19 2007-12-20 Mcnulty Amy K Method for the detection and neutralization of bacteria
KR100781669B1 (ko) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
KR100924661B1 (ko) * 2007-08-16 2009-11-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 포도비리대박테리오파지
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
RU2366456C1 (ru) * 2007-12-17 2009-09-10 Николай Васильевич Пименов Препарат против сальмонеллеза голубей и способ лечения сальмонеллеза голубей
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
RU2375075C1 (ru) * 2008-04-24 2009-12-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН (ВИЭВ) Способ лечения птиц при сальмонеллезе, вызванном salmonella typhimurium
US7745194B2 (en) * 2008-09-16 2010-06-29 Intralytix, Inc. Staphylococcus aureus: bacteriophage and uses thereof
KR101070938B1 (ko) * 2008-12-02 2011-10-06 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
GB2466177A (en) * 2008-12-03 2010-06-16 Arab Science & Technology Found Bacteriophage selection and breeding
KR101151516B1 (ko) * 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
US8771936B2 (en) 2008-12-24 2014-07-08 Cj Cheiljedang Corporation Bacteriophage and antibacterial composition comprising the same
JP5720045B2 (ja) * 2008-12-26 2015-05-20 国立大学法人東京工業大学 スタフィロコッカス・アウレウス溶菌性バクテリオファージ
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
AU2010212280B2 (en) 2009-08-12 2015-09-24 Buddhist Tzu Chi Medical Foundation Phage of acinetobacter Baumannii
WO2011028057A2 (en) * 2009-09-03 2011-03-10 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same
US20110052541A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same
US8846368B2 (en) 2009-09-03 2014-09-30 Cj Cheiljedang Corporation Bacteriophage and antibacterial composition comprising the same
EP2475377B1 (en) * 2009-09-03 2016-01-06 CJ CheilJedang Corporation Novel bacteriophage and antibacterial composition comprising the same
US20110052543A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same
KR101101377B1 (ko) 2009-10-16 2012-01-02 경희대학교 산학협력단 이질균에 특이적 사멸능을 갖는 박테리오파지
TW201130980A (en) * 2010-03-02 2011-09-16 Univ Ishou A new lytic phage specific to Klebsiella pneumoniae
EP3443970B1 (en) 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
US8597928B2 (en) 2010-12-21 2013-12-03 Cj Cheiljedang Corporation Bacteriophage of the siphoviridae family and antibacterial compositions comprising the same
KR101432872B1 (ko) 2011-09-20 2014-08-27 씨제이제일제당 (주) 신규 박테리오파지 및 이를 포함하는 항균 조성물
KR101279780B1 (ko) 2011-10-05 2013-06-28 주식회사 인트론바이오테크놀로지 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지
KR101260645B1 (ko) 2011-11-14 2013-05-03 씨제이제일제당 (주) 대장균 특이적 사멸능을 나타내는 신규 분리된 박테리오파지 및 이를 포함하는 항균 조성물
EP3692999A1 (en) 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
KR101299179B1 (ko) * 2012-04-18 2013-08-22 씨제이제일제당 (주) 신규 박테리오파지 및 이를 포함하는 항균 조성물
KR20230113404A (ko) * 2012-05-09 2023-07-28 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
WO2014150870A2 (en) 2013-03-15 2014-09-25 Altria Client Services Inc. Bacteriophage and methods of making and using
KR101591783B1 (ko) 2014-04-15 2016-02-04 씨제이제일제당(주) 신규 박테리오파지 및 이를 포함하는 조성물
RU2565559C1 (ru) * 2014-11-19 2015-10-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) ШТАММ БАКТЕРИОФАГА Citrobacter freundii CF17, СПОСОБНЫЙ ЛИЗИРОВАТЬ ПАТОГЕННЫЕ ШТАММЫ CITROBACTER FREUNDII
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
US11058131B2 (en) 2015-04-16 2021-07-13 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli O157:H7 bacteriophage Φ241
KR101940019B1 (ko) * 2017-06-19 2019-01-18 연세대학교 산학협력단 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지
KR102011956B1 (ko) * 2017-06-19 2019-08-19 주식회사 마이크로바이오틱스 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지
KR102011965B1 (ko) * 2017-06-19 2019-08-19 주식회사 마이크로바이오틱스 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지
JP2022536960A (ja) * 2019-06-21 2022-08-22 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｌｉｓｔｅｒｉａの検出のための変異体バクテリオファージを生成するための方法
US20230117606A1 (en) * 2020-03-06 2023-04-20 Endolytix Technology, Inc. Compositions and methods for the treatment of intracellular bacterial infections
BR112022017797A2 (pt) * 2020-03-06 2022-11-29 Endolytix Tech Inc Métodos de distribuição de um bacteriófago, de tratamento de uma infecção bacteriana, de isolamento de um fago direcionado a uma bactéria e composição
KR102586836B1 (ko) 2021-02-23 2023-10-10 씨제이제일제당 주식회사 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR102586837B1 (ko) 2021-02-23 2023-10-10 씨제이제일제당 주식회사 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR102586835B1 (ko) 2021-02-23 2023-10-10 씨제이제일제당 주식회사 장독소성 대장균에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR102586839B1 (ko) 2021-02-25 2023-10-10 씨제이제일제당 주식회사 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
KR102586838B1 (ko) * 2021-02-25 2023-10-10 씨제이제일제당 주식회사 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
CN119799652A (zh) * 2024-11-29 2025-04-11 瑞科盟(青岛)生物工程有限公司 一株产酸克雷伯菌噬菌体rdp-ec-23031及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851006A (en) * 1955-11-03 1958-09-09 Swift & Co Hatching of eggs
GB829266A (en) * 1957-03-20 1960-03-02 Biogena A method of manufacturing bacteriophages in solid dry form
US3793151A (en) * 1972-07-10 1974-02-19 J Denney Method of screening for anticapsular substances
SU827064A1 (ru) * 1979-05-17 1981-05-07 Центральный Научно-Исследовательскийордена Ленина И Ордена Трудового Красногознамени Институт Гематологии И Переливаниякрови Способ профилактики эндогенногоиНфициРОВАНи пРи ОСТРыХ лЕйКОзАХ
US4659561A (en) * 1983-02-18 1987-04-21 The University Of Vermont And State Agricultural College Process for treating the oral cavity
SU1153330A1 (ru) * 1983-11-05 1985-04-30 Предприятие П/Я В-8542 Устройство дл делени многочлена на многочлен
US4674480A (en) * 1984-05-25 1987-06-23 Lemelson Jerome H Drug compositions and methods of applying same
US4678750A (en) * 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US4828999A (en) * 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
WO1990003122A1 (en) * 1988-09-26 1990-04-05 Microbial Developments Limited Antimicrobial preparations
US4891210A (en) * 1989-01-03 1990-01-02 Norris Alan H Use of bacteriophages in dental hygiene
GB8913657D0 (en) * 1989-06-14 1989-08-02 Microbial Dev Ltd Ruminant feedstuff additives
GB8918983D0 (en) * 1989-08-21 1989-10-04 Unilever Plc Composition for hygiene purposes
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
SU1685998A1 (ru) * 1989-10-11 1991-10-23 Научно-Производственное Объединение "Бактериофаг" Тбилисского Научно-Исследовательского Института Вакцин И Сывороток Штамм бактериофага ЕNтеRовастеR aeRoGeNeS дл диагностики, профилактики и лечени инфекции, вызываемой ЕNтеRовастеR aeRoGeNeS
ES2016539A6 (es) * 1989-10-18 1990-11-01 Diseno Y Construccion De Mecan Aparato extracor de piezas moldeadas, en especial para maquinas de inyectar plastico.
US4957686A (en) * 1990-02-06 1990-09-18 Norris Alan H Use of bacteriophages to inhibit dental caries
GB2253859A (en) * 1991-02-28 1992-09-23 Microbial Dev Ltd Use of bacteriophages to prevent microbial infestation
RU2036232C1 (ru) * 1992-03-02 1995-05-27 Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Способ получения пиобактериофага
IL112920A (en) * 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
AU699322B2 (en) * 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
CA2199478A1 (en) * 1994-09-09 1996-03-14 Allan L. Delisle Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases
US5656424A (en) * 1995-02-15 1997-08-12 Albert Einstein College Of Medicine, A Division Of Yeshiva University Identification of mycobacterium tuberculosis complex species
US5741697A (en) * 1995-11-30 1998-04-21 University Of Rochester Bacteriophage of chlamydia psittaci
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6322783B1 (en) * 1996-08-26 2001-11-27 Seishi Takahashi Bacteriophages, method for screening same and bactericidal compositions using same, and detection kits using same
US6264945B1 (en) * 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6277399B1 (en) * 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6248324B1 (en) * 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6432444B1 (en) * 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6254866B1 (en) * 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6982153B1 (en) * 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6482632B1 (en) * 1999-03-29 2002-11-19 Council Of Scientic And Industrial Research Bacteriophage, a process for the isolation thereof, and a universal growth medium useful in the process thereof
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2001050872A2 (en) * 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages
US6485902B2 (en) * 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
ATE305793T1 (de) * 2000-07-25 2005-10-15 Us Gov Health & Human Serv Bakteriophage mit breitem wirtspektrum
US6991786B1 (en) * 2000-08-30 2006-01-31 Wisconsin Alumni Research Foundation Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics
MXPA03004182A (es) * 2000-11-13 2004-03-26 Univ Iowa State Res Found Inc Composiciones y metodos para reducir la cantidad de salmonella en el ganado.
US6461608B1 (en) * 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination
US20050118567A1 (en) * 2002-01-23 2005-06-02 Merril Carl R. Method for determining sensitivity to a bacteriophage
US6929798B2 (en) * 2002-02-13 2005-08-16 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US20040157314A1 (en) * 2003-02-07 2004-08-12 Phagetech Inc. Inhibitors of Staphylococcus aureus primary sigma factor and uses thereof
CA2523693A1 (en) * 2003-04-10 2004-10-28 Salisbury University Bacteriophage for lysis of methylobacterium and compositions and uses thereof
US7521201B2 (en) * 2004-11-01 2009-04-21 Strategic Diagnostics Inc. Bacteriophages as selective agents

Also Published As

Publication number Publication date
US20050260171A1 (en) 2005-11-24
WO1997039111A1 (en) 1997-10-23
JP2000508322A (ja) 2000-07-04
AU2500097A (en) 1997-11-07
AU734420B2 (en) 2001-06-14
EP0895534A1 (en) 1999-02-10
US6942858B1 (en) 2005-09-13
US6121036A (en) 2000-09-19

Similar Documents

Publication Publication Date Title
CA2251724A1 (en) Compositions containing bacteriophages and methods of using bacteriophages to treat infections
DE60113851T2 (de) Bakteriophage mit breitem wirtsspektrum
US7807149B2 (en) Bacteriophage-containing therapeutic agents
US7588929B2 (en) Production of bacteriophage compositions for use in phage therapy
Reynaud et al. Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy
JP7370867B2 (ja) 療法バクテリオファージ組成物
Pitt Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis
CN110612349B (zh) 新型铜绿假单胞菌噬菌体Pse-AEP-3及其用于抑制铜绿假单胞菌的增殖的用途
Moody et al. In vitro susceptibility of Pseudomonas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole
EP1406642B1 (en) Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
EP3584315A1 (en) Novel pseudomonas aeruginosa bacteriophage pse-aep-4 and use thereof for inhibiting proliferation of pseudomonas aeruginosa
CN115029322A (zh) 一株多药耐药肺炎克雷伯菌噬菌体及其应用
Esmat et al. Antibiotics and phage sensitivity as interventions for controlling Escherichia coli isolated from clinical specimens
Bergeron et al. In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae
CN115261339B (zh) 一种多重耐药序列383型肺炎克雷伯氏菌噬菌体及其应用
Narulita et al. Potential bacteriophages to overcome bacterial infection of Alcaligenes faecalis in diabetic ulcer
Thomas et al. Bifidobacterium (Actinomyces) eriksonii infection
US20250002869A1 (en) Burkholderia pseudomallei (Bp) phage vB BpP HN01 and use thereof
CN119464231B (zh) 嗜麦芽窄食单胞菌噬菌体、组合物及其应用
Nair et al. The prospects of a highly virulent biofilm dispersing bacteriophage isolated from environment for controlling Enterobacter cloacae in clinical medicine
Al-Hindi et al. Evaluation of the lytic kinetics of a cocktail of two wastewater Siphoviridae bacteriophages against uropathogenic Klebsiella pneumoniae.
Krueger et al. Observations on the bacteriophage in infections of the urinary tract
Davison et al. Isolation of Bacteriophage against Pseudomonas aureginosa from Male Urinary Tract Infection (UTI) Specimen
EP4608423A1 (en) Biocontrol compositions of bacteriophage, methods of producing and uses thereof
CN119432773A (zh) 一株可以清除多重耐药肠球菌的噬菌体efh1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued